Blocking CD73 Can Shrink Pancreatic Tumors.

[Abstract:] A recently reported clinical trial yielded positive results for a CD73 inhibitor that reduces production of immunosuppressive adenosine in patients with pancreatic cancer. The patients, who also received chemotherapy and a PD-1 checkpoint inhibitor, had an overall response rate of 41%. Tumors shrank or stabilized in 85% of patients who received the drug for 16 weeks.